NLC – The European Healthtech Venture Builder and Charles River Laboratories team up to drive drug discovery projects towards finding innovative therapeutics.
Charles River Laboratories (“Charles River”) and NLC- The European Healthtech Venture Builder (“NLC”) have signed a Memorandum of Understanding for future collaborations to advance health through early-stage drug discovery and development.
NLC utilises its extensive biotech and pharmaceutical ecosystem and knowledge to carefully select high-potential, preclinical biotech research. Charles River’s comprehensive preclinical development services and strategy resources provide safer, higher-quality drug discovery and development: supporting the projects of NLC’s portfolio companies together to bring life-saving drugs to patients.
Bert-Arjan Millenaar, CEO, NLC, “Our collaboration with Charles River Laboratories will enable preclinical biotech innovations to reach the clinical phase faster with better candidates, eventually improving the lives of millions of people worldwide.”
NLC and Charles River aim to bring the best of European biotech to the patient quicker, better and safer.